These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17803891)

  • 1. Biotherapies: are they just like any other drugs?
    Paintaud G; Tonelli D; Postaire E;
    Therapie; 2007; 62(3):229-39. PubMed ID: 17803891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interaction studies of therapeutic proteins or monoclonal antibodies.
    Mahmood I; Green MD
    J Clin Pharmacol; 2007 Dec; 47(12):1540-54. PubMed ID: 17962422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term data in the treatment of psoriasis.
    Thaçi D
    Br J Dermatol; 2008 Aug; 159 Suppl 2():18-24. PubMed ID: 18700911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
    Goupille P
    Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic solutions for degenerative disk disease.
    Fassett DR; Kurd MF; Vaccaro AR
    J Spinal Disord Tech; 2009 Jun; 22(4):297-308. PubMed ID: 19494751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cells as vehicles for therapeutic genes to treat liver diseases.
    Prieto J; Fernandez-Ruiz V; Kawa MP; Sarobe P; Qian C
    Gene Ther; 2008 May; 15(10):765-71. PubMed ID: 18385768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.
    Arnett HA; Viney JL
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1084-92. PubMed ID: 17804112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gene-engineering technologies and stem cells].
    Spivak NIa; Sukhikh GT; Bogdanova IM; Malaĭtsev VV; Shevchuk VA
    Fiziol Zh (1994); 2008; 54(3):92-104. PubMed ID: 18763585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-binding cavities in long-lived biologics: cause for concern but also potential benefit.
    Panayotatos N
    J Clin Pharmacol; 2008 Oct; 48(10):1208-11. PubMed ID: 18812610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells.
    Moi P; Sadelain M
    Haematologica; 2008 Mar; 93(3):325-30. PubMed ID: 18310536
    [No Abstract]   [Full Text] [Related]  

  • 16. Stem cell antigen-1+ cell-based bone morphogenetic protein-4 gene transfer strategy in mice failed to promote endosteal bone formation.
    Hall SL; Chen ST; Gysin R; Gridley DS; Mohan S; Lau KH
    J Gene Med; 2009 Oct; 11(10):877-88. PubMed ID: 19629966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats.
    Miyazaki M; Sugiyama O; Tow B; Zou J; Morishita Y; Wei F; Napoli A; Sintuu C; Lieberman JR; Wang JC
    J Spinal Disord Tech; 2008 Jul; 21(5):372-9. PubMed ID: 18600149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in monoclonal antibody-based therapies.
    Samaranayake H; Wirth T; Schenkwein D; Räty JK; Ylä-Herttuala S
    Ann Med; 2009; 41(5):322-31. PubMed ID: 19234897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues.
    Rao M
    Gene Ther; 2008 Jan; 15(2):82-8. PubMed ID: 18004405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periodontal regeneration using ex vivo autologous stem cells engineered to express the BMP-2 gene: an alternative to alveolaplasty.
    Chen YL; Chen PK; Jeng LB; Huang CS; Yang LC; Chung HY; Chang SC
    Gene Ther; 2008 Nov; 15(22):1469-77. PubMed ID: 18701911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.